Virax Biolabs Group Limited (VRAX)
NASDAQ: VRAX · Real-Time Price · USD
0.134
-0.007 (-5.24%)
At close: Apr 28, 2026, 4:00 PM EDT
0.139
+0.005 (3.81%)
After-hours: Apr 28, 2026, 7:12 PM EDT
Virax Biolabs Group Stock Forecast
VRAX's stock price has decreased by -87.26% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Virax Biolabs Group stock has a target of 1.00, which predicts an increase of 647.38% from the current stock price of 0.13.
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 9, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Virax Biolabs Group is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $3 → $1 | Strong Buy | Reiterates | $3 → $1 | +647.38% | Jan 9, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $3 | Strong Buy | Initiates | $3 | +2,142.15% | Mar 31, 2025 |
Financial Forecast
Revenue This Year
13.76M
from 6.33K
Increased by 217,274.82%
Revenue Next Year
4.08M
from 13.76M
Decreased by -70.35%
EPS This Year
0.04
from -1.62
EPS Next Year
n/a
from 0.04
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 14.2M | 4.2M |
| Avg | 13.8M | 4.1M |
| Low | 13.2M | 3.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | 223,671.9% | -69.5% |
| Avg | 217,274.8% | -70.4% |
| Low | 208,745.4% | -71.5% |
EPS Forecast
| EPS | 2026 |
|---|---|
| High | 0.04 |
| Avg | 0.04 |
| Low | 0.04 |
EPS Growth
| EPS Growth | 2026 |
|---|---|
| High | - |
| Avg | - |
| Low | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.